Core Insights - Jingtai Holdings (02228) demonstrated strong market appeal and execution capability through a textbook "lightning placement" by announcing a placement of up to approximately 286 million shares, raising HKD 2.65 billion [1] - The placement price was set at HKD 9.28 per share, representing a premium of approximately 75.8% over the IPO price and about 23.4% over the average closing price of the last 30 trading days, indicating high market recognition of the company's value [1] - The placement attracted significant interest from various institutional investors, including Norges Bank Investment Management, the world's largest sovereign wealth fund, reflecting strong confidence in the company's growth prospects [2] Financial Performance - In the first half of 2025, Jingtai Holdings achieved scale profitability for the first time, with revenue from drug discovery solutions increasing by 615.2% to HKD 435 million, and revenue from intelligent robotics solutions rising by 95.9% to HKD 82 million [2] - As of August 27, 2025, the company's market capitalization exceeded HKD 41.2 billion, making it the highest-valued company in the Asian AI drug discovery sector [2] - The company has a robust cash reserve of HKD 5.308 billion as of June 30, 2025, which, combined with the new financing, brings total cash reserves to approximately HKD 8 billion, providing a strong financial foundation for continued leadership in the field [3] Strategic Initiatives - Jingtai Holdings plans to utilize the proceeds from the placement for product and research iteration, commercialization expansion, and potential mergers and acquisitions, while also exploring innovative financial tools such as RWA (Real World Assets) and RDA (Real Data Assets) [1][4] - The company’s AI and robotics molecular discovery platform aligns well with the newly launched RWA registration platform in Hong Kong, which aims to facilitate the tokenization of real-world assets, enhancing asset liquidity and broadening financing channels for innovative drug development [4]
“AI for Science第一股”晶泰控股完成近30亿港元新股配售融资 登顶全球AI制药融资王